Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Talaris Therapeutics, Inc. (TALS : NSDQ)
 
 • Company Description   
Talaris Therapeutics Inc. is a late-clinical stage cell therapy company. It involved in developing a method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. Talaris Therapeutics Inc. is based in BOSTON.

Number of Employees: 82

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.75 Daily Weekly Monthly
20 Day Moving Average: 81,626 shares
Shares Outstanding: 41.35 (millions)
Market Capitalization: $527.28 (millions)
Beta:
52 Week High: $19.82
52 Week Low: $11.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.16% -17.67%
12 Week -8.99% -9.90%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
570 SOUTH PRESTON STREET
-
LOUISVILLE,KY 40202
USA
ph: 502-398-9250
fax: -
None http://talaristx.com
 
 • General Corporate Information   
Officers
Scott Requadt - Chief Executive Officer and President
Francois Nader - Chairman
Mary Kay Fenton - Chief Financial Officer
Sandip Agarwala - Director
Nicholas G. Galakatos - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 87410C104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/11/22
Share - Related Items
Shares Outstanding: 41.35
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $527.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.54 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.06
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 21.95%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -36.84
06/30/21 - -74.09
03/31/21 - -
ROA
09/30/21 - -19.41
06/30/21 - -23.73
03/31/21 - -36.49
Current Ratio
09/30/21 - 51.83
06/30/21 - 58.03
03/31/21 - 39.88
Quick Ratio
09/30/21 - 51.83
06/30/21 - 58.03
03/31/21 - 39.88
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 6.18
06/30/21 - 6.59
03/31/21 - -6.45
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - -
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - -
 

Powered by Zacks Investment Research ©